VIM and lung cancer: The obtained results are in accordance with our previously published study indicating that baseline Vim+ aneuploid circulating rare cells including CD31+ CTECs significantly correlated with poor prognosis as well as distant hepatic metastasis in advanced lung cancer patients [49].